Loading...
Loading...
MCRB| Name | Value |
|---|---|
| Revenues | 0.3M |
| Cost of Revenue | 0.5M |
| Gross Profit | -0.2M |
| Operating Expense | 47.7M |
| Operating I/L | -47.4M |
| Other Income/Expense | 1.0M |
| Interest Income | 2.6M |
| Pretax | -47.9M |
| Income Tax Expense | 1.4M |
| Net Income/Loss | -47.9M |
Seres Therapeutics, Inc. is a microbiome therapeutics platform company specializing in developing bacterial consortia to treat diseases. Its lead product candidate, SER-109, has completed Phase III clinical trial for clostridium difficile infection (CDI). The company is also developing SER-155, a cultivated bacteria microbiome drug, and other candidates for gastrointestinal infections, ulcerative colitis, metastatic melanoma, and more. Seres Therapeutics generates revenue through the development and commercialization of its microbiome therapeutic candidates, as well as through license and collaboration agreements with partners such as Nestec Ltd. and Memorial Sloan Kettering Cancer Center.
